Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).

Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). Abstract Text:

Pablo Tebas,Jiameng Zhang,Kevin Yarasheski,Scott Evans,Margaret A Fischl,Abby Shevitz,Judith Feinberg,Ann C Collier,Cecilia Shikuma,Barbara Brizz,Fred Sattler, ,

BACKGROUND: Subcutaneous limb fat loss continues to be one the most troubling side effects of long-term antiretroviral regimens. Nucleoside analogues and protease inhibitors (PIs) have been linked to the development of this complication. METHODS: We evaluated the effects of nucleoside-sparing and PI-sparing regimens on fat distribution, bone mineral density, and metabolic parameters in 62 subjects, who were not selected for lipoatrophy, with advanced HIV (nadir CD4 count or=80,000 copies/mL) and an undetectable HIV viral load. Participants were randomized to switch their initial successful antiretroviral regimen to open-label lopinavir/ritonavir (LPV/r) at a dose of 533/133 mg twice a day and efavirenz (EFV) at a dose of 600 mg/d (the nucleoside-sparing arm) versus EFV and 2 nucleoside analogues (the PI-sparing arm). FINDINGS: At week 48, the median change in limb fat in the nucleoside-sparing arm was 562 g (6%, interquartile range [IQR]: -218-1186 g) versus a loss of -242 g (-4%, IQR: -539-452 g) in the nucleoside-containing PI-sparing arm (P = 0.086). At the time of last observation (median = 102 weeks, IQR: 73-152 weeks), a median gain of 782 g (10%, IQR: -380-1168 g) of limb fat was noted in the nonnucleoside arm (n = 22) versus a loss of 850 g (-15%, IQR: -1270 to -526 g) in the nucleoside-containing arm (n = 25; P = 0.002). INTERPRETATION: The switch to a nucleoside-sparing combination antiretroviral regimen (LPV/r + EFV) was associated with significant improvement in limb fat. These results provide additional evidence that nucleoside analogues are important in the progressive limb fat loss that characterizes antiretroviral treatment and that switching medications can significantly improve this complication. This option has to be carefully balanced with the potential to increase serum lipid levels and the trend to increase virologic failure.

Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). Publishing Authors By Initials

P Tebas,J Zhang,K Yarasheski,S Evans,MA Fischl,A Shevitz,J Feinberg,AC Collier,C Shikuma,B Brizz,F Sattler, ,

For similar natural sciences: time: time factors research abstracts see: natural sciences: time: time factors research

PUBMED ID PMID:

MEDLINE DATE:

Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of acquired immune deficiency syndromes (1

VOLUME: 45

Page Numbers: 193-200

Journal Abbreviation: J. Acquir. Immune Defic. Syndr

ISSN: 1525-4135

DAY: 1

MONTH: Jun

YEAR: 2007

Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100892005

Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). Keywords Mesh Terms:

KEYWORDS: Time Factors

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). Information

Substance Name: lopinavir

Registry Number: 192725-17-0

Grant and Affiliation Information for Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).

AFFILIATION: Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA 19104, USA. pablo.tebas@uphs.upenn.edu

Country: United States

AGENCY: United States NIAID

GRANT: R21AI063995

ACRONYM: AI

MEDLINETA: J Acquir Immune Defic Syndr

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Switching to a protease inhibitor-containing, nucleoside-sparing regimen lopinavir/ritonavir plus efavirenz increases limb fat but raises serum lipid levels: results of a prospective randomized trial AIDS clinical trial group 5125s Related Publications

• Butyrolactone I Derivatives from Aspergillus terreus Carrying an Unusual Sulfate Moiety.
• Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications.
• Comparison of RRR-alpha- and all-rac-alpha-tocopherol uptake by permanent rat skeletal muscle myoblasts (L6 cells): effects of exogenous lipoprotein lipase.
• Connection piece for hearing device support hook.
• Decreasing asthmagens in hospitals.
• Dynamic effects on j-couplings across hydrogen bonds in proteins.
• Improving outcomes in pediatric procedural sedation.
• Inhibition of lung carcinoma cell growth by high density lipoprotein-associated alpha-tocopheryl-succinate.
• Lipoprotein-associated alpha-tocopheryl-succinate inhibits cell growth and induces apoptosis in human MCF-7 and HBL-100 breast cancer cells.
• New Abietane Diterpenoids from the Mangrove Avicennia marina.
• New report on decreasing asthmagens in hospitals.
• Our bodies and the legacy of "better living through chemistry.
• Pathogenesis and treatment of lipodystrophy: what clinicians need to know.
• Reliability of maximal voluntary muscle strength and power testing in older men.
• Results of alloarthroplasty of the hip joint.
• Site-specific variations of carbonyl chemical shift anisotropies in proteins.
• Structure and functional analysis of the MYND domain.
• Structure, derivatization, and antitumor activity of new griseusins from Nocardiopsis sp.
• Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).
• The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.
• [Demonstration of I/i- and Pr-antigens on lymphocytes by cold agglutinins (proceedings)]
• [Esophagus carcinoma in young adults.]
• [Experiences with a barbituric acid-free hypnotic combination.]
• [Not Available.]